ECSP034487A - Uso de una combinacion de salmeterol y fluticasona - Google Patents

Uso de una combinacion de salmeterol y fluticasona

Info

Publication number
ECSP034487A
ECSP034487A EC2003004487A ECSP034487A ECSP034487A EC SP034487 A ECSP034487 A EC SP034487A EC 2003004487 A EC2003004487 A EC 2003004487A EC SP034487 A ECSP034487 A EC SP034487A EC SP034487 A ECSP034487 A EC SP034487A
Authority
EC
Ecuador
Prior art keywords
salmeterol
fluticasona
combination
combinations
treatment
Prior art date
Application number
EC2003004487A
Other languages
English (en)
Inventor
Donald Herbert Horstman
Claire Julia Maden
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ECSP034487A publication Critical patent/ECSP034487A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment Of Water By Ion Exchange (AREA)

Abstract

Este invento se refiere al uso de las combinaciones del salmeterol y propionato de fluticasona para el tratamiento de la enfermedad pulmonar obstructiva crónica.
EC2003004487A 2000-08-31 2003-02-20 Uso de una combinacion de salmeterol y fluticasona ECSP034487A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22938100P 2000-08-31 2000-08-31

Publications (1)

Publication Number Publication Date
ECSP034487A true ECSP034487A (es) 2003-03-31

Family

ID=22860986

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004487A ECSP034487A (es) 2000-08-31 2003-02-20 Uso de una combinacion de salmeterol y fluticasona

Country Status (24)

Country Link
US (1) US20040009963A1 (es)
EP (1) EP1313484A2 (es)
JP (1) JP2004507494A (es)
KR (1) KR20030031997A (es)
CN (1) CN1449288A (es)
AP (1) AP2003002753A0 (es)
AR (1) AR030516A1 (es)
AU (1) AU2001284236A1 (es)
BG (1) BG107596A (es)
BR (1) BR0113555A (es)
CA (1) CA2420532A1 (es)
EA (1) EA200300152A1 (es)
EC (1) ECSP034487A (es)
HU (1) HUP0303755A2 (es)
IL (1) IL154403A0 (es)
MA (1) MA25834A1 (es)
MX (1) MXPA03001752A (es)
NO (1) NO20030899L (es)
OA (1) OA12370A (es)
PE (1) PE20020387A1 (es)
PL (1) PL365582A1 (es)
SK (1) SK2302003A3 (es)
WO (1) WO2002017894A2 (es)
ZA (1) ZA200301475B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0106031D0 (en) * 2001-03-12 2001-05-02 Glaxo Group Ltd Use
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
AU2003254429A1 (en) * 2003-08-06 2005-02-25 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
TR200907913A2 (tr) * 2009-10-20 2011-05-23 Bi̇lgi̇ç Mahmut İnhalason yolu ile alınmak üzere kuru toz formunda farmasötik bileşim
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
TR201000681A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut İnhalasyon yoluyla alınan kuru toz formülasyonları.
TR200909791A2 (tr) * 2009-12-25 2011-07-21 B�Lg�� Mahmut Salmeterol ve flutikazon içeren farmasötik bileşim@
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
US20150224197A1 (en) * 2012-07-05 2015-08-13 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation compositions
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
AU2014261538A1 (en) * 2013-04-29 2015-12-10 Sanofi Sa Inhalable pharmaceutical compositions and the inhaler devices containing them
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
EP4568677A1 (en) * 2022-08-08 2025-06-18 Verona Pharma PLC Ensifentrine (rpl-554) for increasing trough lung function
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9808802D0 (en) * 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
GB9924992D0 (en) * 1999-10-21 1999-12-22 Glaxo Group Ltd Pharmaceutical aerosol formulations
EP1248597B1 (en) * 1999-12-24 2005-03-30 Glaxo Group Limited Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate

Also Published As

Publication number Publication date
HUP0303755A2 (hu) 2004-04-28
PE20020387A1 (es) 2002-06-24
MXPA03001752A (es) 2003-06-04
KR20030031997A (ko) 2003-04-23
ZA200301475B (en) 2004-05-24
AR030516A1 (es) 2003-08-20
OA12370A (en) 2004-03-19
WO2002017894A2 (en) 2002-03-07
NO20030899D0 (no) 2003-02-26
NO20030899L (no) 2003-04-28
SK2302003A3 (en) 2003-08-05
MA25834A1 (fr) 2003-07-01
BR0113555A (pt) 2003-07-22
EP1313484A2 (en) 2003-05-28
CN1449288A (zh) 2003-10-15
JP2004507494A (ja) 2004-03-11
AU2001284236A1 (en) 2002-03-13
IL154403A0 (en) 2003-09-17
PL365582A1 (en) 2005-01-10
EA200300152A1 (ru) 2003-08-28
AP2003002753A0 (en) 2003-06-30
US20040009963A1 (en) 2004-01-15
BG107596A (bg) 2004-01-30
CA2420532A1 (en) 2002-03-07
WO2002017894A3 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
AR030516A1 (es) Uso de una combinacion de salmeterol y fluticasona
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
AR028238A1 (es) Tratamiento para el tabaco
AR028423A1 (es) Inhibidores de la replicacion del hiv
CO5140098A1 (es) Combinaciones de un agonista de betra-2 y un esteroide, su uso para tratamiento de enfermedades inflamatorias u obstructivas de las vias aereas
ATE276244T1 (de) Replikationsinhibitoren des respiratorischen synzytialvirus
PT1605956E (pt) Administração de capsaicinóides para o tratamento da osteoartrite
CY2016031I2 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
ATE486840T1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
EP2019825A4 (en) HEMMER OF THE REPRODUCTION OF HUMAN IMMUNE DEFICIENCY VIRUSES
IS7010A (is) Lyfjaform ókristallaðs nelfinavir mesylate
DE60137361D1 (de) Piezoelektrische keramik
DE60109044D1 (de) Arzneimittel zur behandlung der mucositis, stomatitis und des behcetschen syndroms
EE05020B1 (et) Glburiidi ravimkoostis
AR028355A1 (es) Compuestos para el tratamiento de la fibromialgia y el sindrome de fatiga cronica
MXPA03006014A (es) Dentifrico de componente dual para reducir los olores de la boca.
ECSP088287A (es) Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
ATE348617T1 (de) Heilmittel gegen durch endothelin verursachte erkrankungen
ECSP014082A (es) Combinacion de secretagogos de hormona del crecimiento y antidepresivos
NO20012831D0 (no) Diazepinoindoler for behandling av kronisk obstruktiv lungesykdom
EP1594435A4 (en) INHIBITION OF HIV-1 REPLICATION BY TREATMENT OF THE PROCESSING OF THE VIRAL CAPSID-SPACER PEPTIDE 1 PROTEIN
UY26912A1 (es) Uso de una combinación de salmeterol y fluticasona
AR053032A1 (es) Uso de farmacos antiinflamatorios no esteroides por via inhalatoria en la terapia de la bronquitis aguda y cronica
PT1276495E (pt) Utilizacao de tensioactivo pulmonar recombinante para o tratamento precoce de doencas pulmonares agudas